Skip to main content
58 search results for:

Tumor mutational burden 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 23-06-2022 | Non-small-cell lung cancer | News | Article

    Tumor mutational burden ‘valuable biomarker’ for ICI response in NSCLC

    High tumor mutational burden is associated with a better response to immune checkpoint inhibitors in people with non-small-cell lung cancer across all levels of PD-L1 expression, US researchers report.

  2. 16-04-2018 | Non-small-cell lung cancer | Article

    Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    Hellmann MD et al. N Eng J Med 2018. 10.1056/NEJMoa1801946

  3. 01-09-2022 | Non-small-cell lung cancer | News | Article

    BFAST trial: More work needed to optimize blood TMB as immunotherapy biomarker

    Data from the BFAST study suggest that blood-based tumor mutational burden at a cutoff of 16 mutations does not predict first-line atezolizumab outcomes in people with advanced non-small-cell lung cancer.

  4. 14-10-2022 | Non-small-cell lung cancer | News | Article

    CHOICE-01 shows survival benefit of adding toripalimab to chemo in advanced NSCLC

    But the team observed “a positive interaction” between tumor mutational burden (TMB) and toripalimab treatment, such that TMB-high (≥10 mutations/Mb) patients derived a greater PFS benefit from the use of toripalimab instead of placebo than their TMB-low counterparts (hazard ratios=0.34 and 0.62, respectively).

  5. 04-07-2022 | Breast cancer | News | Article
    guidelinesWatch

    ASCO updates multiple advanced breast cancer guidelines

    The new topics range from testing for somatic PIK3CA and ESR1 variants and germline BRCA1 , BRCA2 , and PALB2 variants to guide targeted therapy to evaluating PD-L1 expression in tumor and immune cells, tumor mutational burden (TMB), and deficient mismatch repair/microsatellite instability to aid immunotherapy decisions.

  6. 28-06-2022 | Non-small-cell lung cancer | News | Article

    Neutrophil to lymphocyte ratio may help identify ICI candidates in NSCLC

    Exploratory analyses revealed that individuals with a high blood tumor mutational burden (TMB; ≥16 mutations/Mb) had a significantly higher median NLR at baseline than those with a low TMB, at 4.6 versus 3.7, but the researchers say this could possibly be explained by the positive relationships they observed between NLR and smoking, and NLR and the number of metastatic sites.

  7. 10-12-2021 | SABCS 2021 | Conference coverage | Article

    Dual checkpoint inhibition shows promise for highly mutated HER2-negative MBC

    Dual checkpoint inhibition with nivolumab plus ipilimumab may be a promising treatment option for people with HER2-negative metastatic breast cancer and high tumor mutational burden, phase 2 NIMBUS study data show.

  8. 06-05-2021 | Breast cancer | News | Article

    TAPUR corroborates pembrolizumab benefit in TMB-high metastatic breast cancer

    Heavily pretreated patients with metastatic breast cancer characterized by a high tumor mutational burden are likely to derive “meaningful clinical benefit” from pembrolizumab monotherapy, say the TAPUR researchers.

  9. 30-07-2021 | Non-small-cell lung cancer | News | Article

    No survival benefit with second-line ipilimumab plus nivolumab in advanced squamous NSCLC

    However, a post-hoc exploratory analysis revealed that in the subgroup of patients with no PD-L1 expression (<1%), OS was better with the combination than nivolumab alone among those with a high tumor mutational burden (TMB; ≥10 mutations/Mb), whereas the combination appeared to be detrimental for patients with a TMB below the cutoff.

  10. 16-07-2021 | Immunotherapy | News | Article

    Ex vivo tumor platform gives window to PD-1 blockade response

    A patient-derived tumor fragment platform has allowed close examination of the early immunologic responses to PD-1 blockade, revealing a relationship between immune cell reactivation and clinical response.

  11. 12-10-2020 | Immunotherapy | News | Article

    MUC16 a promising biomarker of ICI response

    Patients with solid tumors harboring MUC16 mutations may have better outcomes in response to immune checkpoint inhibitor therapy than those carrying the wild-type gene, research suggests.

  12. 15-10-2020 | Breast cancer | News | Article

    No benefit of adding pembrolizumab to eribulin for metastatic breast cancer

    But patients with a high tumor mutational burden had a numerically better PFS with pembrolizumab plus eribulin than those given eribulin alone.

  13. 25-09-2020 | ESMO 2020 | Conference coverage | Article

    Long-term ES-SCLC outcomes on durvalumab–chemotherapy predicted by PFS duration

    And tissue tumor mutational burden (TMB), data on which were available for 283 patients, was not significantly associated with rates of long-term benefit in any of the treatment regimens.

  14. 19-06-2020 | FDA | News | Article
    approvalsWatch

    Pembrolizumab approved for advanced TMB-H solid tumors

    medwireNews : Pembrolizumab has been given accelerated approval by the US FDA  for the treatment of unresectable or metastatic solid malignancies with a high tumor mutational burden (TMB-H).

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.